ReviewPaediatric drugs2010
New antimicrobial strategies in cystic fibrosis.
Review in Paediatric drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Dental caries prevalence in children and adolescents with cystic fibrosis: a qualitative systematic review and recommendations for future research.International journal of paediatric dentistry · 2013Pooled it
- Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.American journal of respiratory and critical care medicine · 2012Trial
- Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis.Frontiers in bioengineering and biotechnology · 2019Review
- Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.BMJ open respiratory research · 2015Article
- Related factors of dental caries and molar incisor hypomineralisation in a group of children with cystic fibrosis.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2014Article
- Review
- Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Review
- Adverse drug reactions in hospitalised children in Germany are decreasing: results of a nine year cohort-based comparison.PloS one · 2012Article
- Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.P & T : a peer-reviewed journal for formulary management · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With more antibiotic resistance and emerging pathogens in cystic fibrosis (CF) patients, the need for new strategies in the lifelong treatment of pulmonary infection has increased. Most of the focus is on chronic infection with Pseudomonas aeruginosa, which is still thought to be the main pathogen leading to advanced CF lung disease. Other bacterial species are also recognized in the pathogenesis of CF lung disease, even though their definitive role is not well established yet. Clearly, expansion of treatment options is urgently needed. This article focuses on recent developments in the field of new antimicrobial strategies for CF. It is clear that studies on new classes of antibiotics or antimicrobial-like drugs are scarce, and that most studies involve new (inhalation) formulations, new routes of delivery, or analogs of existing classes of antibiotics. Studies of new antibiotic-like drugs are, in most cases, in preclinical phases of development and only a few of these agents may reach the market. Importantly, new inhaled antibiotics, e.g. aztreonam, levofloxacin, and fosfomycin, and new, more efficient delivery systems such as dry powder inhalation and liposomes for current antibiotics are in the clinical phase of development. These developments will be of great importance in improving effective treatment and reducing the treatment burden for CF patients in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.